The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.
Global X Genomics & Biotechnology ETF GNOM
Morningstar’s Analysis GNOM
Will GNOM outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 41.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Bio-Techne Corp | 4.77 | 4.7 Mil | Healthcare |
Moderna Inc | 4.46 | 4.4 Mil | Healthcare |
Intellia Therapeutics Inc | 4.46 | 4.4 Mil | Healthcare |
Natera Inc | 4.34 | 4.3 Mil | Healthcare |
Agilent Technologies Inc | 4.11 | 4.1 Mil | Healthcare |
Qiagen NV | 4.05 | 4.0 Mil | Healthcare |
Arrowhead Pharmaceuticals Inc | 3.93 | 3.9 Mil | Healthcare |
Sarepta Therapeutics Inc | 3.91 | 3.9 Mil | Healthcare |
BioNTech SE ADR | 3.86 | 3.8 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 3.85 | 3.8 Mil | Healthcare |